Neoadjuvant chemotherapy (NAC) is now widely used in patients with early BC, to achieve breast-conserving surgery (BCS) through prior tumor size reduction, and it is now a standard of care for patients with HER2-positive BC [3,4,5,6,7]. This evidence concerns the gene ERBB2 and breast cancer.